NASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis $54.09 -1.84 (-3.29%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$53.21▼$56.3650-Day Range$51.22▼$60.1652-Week Range$25.98▼$110.25Volume1.40 million shsAverage Volume2.32 million shsMarket Capitalization$5.67 billionP/E RatioN/ADividend YieldN/APrice Target$80.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cytokinetics alerts: Email Address Cytokinetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside49.1% Upside$80.67 Price TargetShort InterestBearish16.38% of Float Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.42Based on 30 Articles This WeekInsider TradingSelling Shares$7.98 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.10) to ($4.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.98 out of 5 starsMedical Sector175th out of 910 stocksPharmaceutical Preparations Industry68th out of 426 stocks 4.4 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 11 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageCytokinetics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cytokinetics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.38% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Cytokinetics has recently increased by 4.49%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 71.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.83. Previous Next 1.9 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Cytokinetics this week, compared to 9 articles on an average week.Search InterestOnly 3 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,981,849.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Cytokinetics is held by insiders.Read more about Cytokinetics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($5.10) to ($4.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -10.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -10.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytokinetics has a P/B Ratio of 58.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cytokinetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Cytokinetics Stock (NASDAQ:CYTK)Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More CYTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Stock News HeadlinesSeptember 4 at 4:21 AM | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) CEO Sells 5,000 Shares of StockAugust 14, 2024 | insidertrades.comRobert I. Blum Sells 11,500 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 13, 2024 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) Director B Lynne Parshall Sells 5,000 SharesAugust 13, 2024 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum Sells 11,500 SharesAugust 9, 2024 | insidertrades.comFady Ibraham Malik Sells 7,300 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockAugust 8, 2024 | insidertrades.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 7,300 Shares of StockSeptember 6 at 6:45 AM | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Given New $71.00 Price Target at JPMorgan Chase & Co.September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 5 at 7:34 PM | markets.businessinsider.comBuy Rating Reaffirmed for Cytokinetics on Aficamten’s Promising Data and Market Outperform PotentialSeptember 5 at 4:00 PM | globenewswire.comCytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual MeetingSeptember 5 at 4:51 AM | americanbankingnews.comFady Ibraham Malik Sells 7,384 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockSeptember 5 at 3:55 AM | americanbankingnews.comCytokinetics' (CYTK) "Market Outperform" Rating Reiterated at JMP SecuritiesSeptember 5 at 2:45 AM | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Rating Reiterated by Needham & Company LLCSeptember 4 at 4:00 PM | globenewswire.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4 at 3:46 PM | markets.businessinsider.comCytokinetics Hold Rating Affirmed Amid Incremental Drug Updates and Competitive UncertaintiesSeptember 4 at 3:46 PM | markets.businessinsider.comTruist Financial Issues a Buy Rating on Cytokinetics (CYTK)September 4 at 4:57 AM | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum Sells 5,000 SharesSee More Headlines Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees250Year Founded1997Price Target and Rating Average Stock Price Target$80.67 High Stock Price Target$106.00 Low Stock Price Target$60.00 Potential Upside/Downside+49.1%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($5.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-526,240,000.00 Net Margins-17,398.82% Pretax Margin-17,398.82% Return on EquityN/A Return on Assets-55.97% Debt Debt-to-Equity Ratio5.93 Current Ratio10.39 Quick Ratio10.39 Sales & Book Value Annual Sales$3.13 million Price / Sales1,809.69 Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book58.79Miscellaneous Outstanding Shares104,854,000Free Float101,289,000Market Cap$5.67 billion OptionableOptionable Beta0.77 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Robert I. Blum (Age 60)CEO, President, Principal Financial Officer & Director Comp: $1.33MMr. Robert C. Wong (Age 56)VP & Chief Accounting Officer Comp: $495.72kDr. Fady Ibraham Malik FACC (Age 60)M.D., Ph.D., Executive Vice President of Research & Development Comp: $839.66kMr. Andrew M. Callos (Age 55)Executive VP & Chief Commercial Officer Comp: $752.84kDr. James A. Spudich Ph.D. (Age 82)Co-Founder & Member of Scientific Advisory Board Comp: $21.94kMr. Jeff LotzVice President of Sales & OperationsMr. Matt YangVice President of Corporate Finance and Financial Planning & AnalysisMr. Steven M. Cook (Age 65)Senior Vice President of Global Supply Chain Operations & Technical Operations Ms. Kari K. Loeser J.D.VP & Chief Compliance OfficerMr. John O. Faurescu Esq.VP, Associate General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsConstellation PharmaceuticalsNASDAQ:CNSTZogenixNASDAQ:ZGNXPhathom PharmaceuticalsNASDAQ:PHATIntercept PharmaceuticalsNASDAQ:ICPTORIC PharmaceuticalsNASDAQ:ORICView All CompetitorsInsiders & InstitutionsGhisallo Capital Management LLCBought 196,000 shares on 9/4/2024Ownership: 0.167%Robert I BlumSold 5,000 sharesTotal: $285,150.00 ($57.03/share)Fady Ibraham MalikSold 7,384 sharesTotal: $420,961.84 ($57.01/share)Cetera Investment AdvisersBought 15,366 shares on 8/22/2024Ownership: 0.026%Murchinson Ltd.Sold 25,000 shares on 8/16/2024Ownership: 0.080%View All Insider TransactionsView All Institutional Transactions CYTK Stock Analysis - Frequently Asked Questions How have CYTK shares performed this year? Cytokinetics' stock was trading at $83.49 at the beginning of 2024. Since then, CYTK stock has decreased by 35.2% and is now trading at $54.09. View the best growth stocks for 2024 here. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) issued its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.06) by $0.25. The company's revenue was down 71.3% compared to the same quarter last year. What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. Who are Cytokinetics' major shareholders? Cytokinetics' top institutional shareholders include Darwin Global Management Ltd. (4.36%), Marshall Wace LLP (1.60%), Integral Health Asset Management LLC (0.95%) and Pentwater Capital Management LP. Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, Ching Jaw, John T Henderson, B Lynne Parshall, Wendall Wierenga, Muna Bhanji, Robert Wong, Robert Arthur Harrington, Santo J Costa, Edward M Md Kaye, Mark A Schlossberg, L Patrick Gage, David Cragg and Sandford D Smith. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO) and Sorrento Therapeutics (SRNE). This page (NASDAQ:CYTK) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
